Stockscreener 앱 받기
4.17
0.95%
-0.04
시장 영업 전:
4.30
0.13
+3.12%
Cingulate Inc 주식(CING)의 최신 뉴스
Analyzing drawdowns of Cingulate Inc. with statistical toolsTrade Ideas Based on Fundamental Metrics - Newser
Why Cingulate Inc. Equity Warrant is moving todayFree Chart Driven High Reward Trading Setup - Newser
Identifying reversal signals in Cingulate Inc. Equity WarrantAI Powered Buy Point Forecast Planner - Newser
How to read the order book for Cingulate Inc.Free Trade Scanner With Buy Zone Alerts - Newser
Smart tools for monitoring Cingulate Inc.’s price actionFree Short Term Setup With Predictive Chart - Newser
Does Cingulate Inc. Equity Warrant show high probability of reboundFree Triple Return Setup with Risk Control - Newser
Is Cingulate Inc. Equity Warrant reversing from oversold territoryReal Time Stock Movement and Alerts - Newser
Understanding Cingulate Inc.’s price movementFree Pattern Alert With ROI Driven Strategy - Newser
What technical models suggest about Cingulate Inc.’s comebackTechnical Insight Guide for Safer Trades - Newser
Using R and stats models for Cingulate Inc. Equity Warrant forecastingSwing Reversal Forecast Based on Patterns - Newser
Using data filters to optimize entry into Cingulate Inc. Equity WarrantEntry Timing with Downside Risk Analysis - Newser
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301 - TipRanks
What momentum shifts mean for Cingulate Inc.Swing Trade Timing with Daily Forecast - Newser
Cingulate Inc.’s Strategic Partnerships and NDA Submission Drive Buy Rating - TipRanks
Cingulate submits CTx-1301 NDA to FDA - TipRanks
Cingulate submits NDA for ADHD treatment to FDA By Investing.com - Investing.com Nigeria
Cingulate Inc Submits NDA for ADHD Treatment - TipRanks
Cingulate submits NDA for ADHD treatment to FDA - Investing.com
Cingulate Submits New Drug Application for ADHD Asset CTx-1301 to FDA - AInvest
Cingulate Submits NDA for CTx-1301, ADHD Treatment with Extended-Release Tablet - AInvest
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 - GlobeNewswire
META Gets Huge Upgrades: How High Analysts Think Shares Could Go - The Globe and Mail
How many analysts rate Cingulate Inc. Equity Warrant as a “Buy”Unlock exclusive stock market insights - Jammu Links News
Cingulate Inc. Stock Analysis and ForecastDiscover breakthrough investment opportunities - Jammu Links News
What is Cingulate Inc. company’s growth strategyRapid market gains - Jammu Links News
How does Cingulate Inc. Equity Warrant generate profit in a changing economyMaximize returns with smart investment plans - Jammu Links News
How many analysts rate Cingulate Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How strong is Cingulate Inc. company’s balance sheetMaximize portfolio growth with strategic plans - Jammu Links News
When is Cingulate Inc. stock expected to show significant growthMarket-leading capital gains - Jammu Links News
What drives Cingulate Inc. stock priceRapid wealth multiplication - Jammu Links News
Why is Cingulate Inc. stock attracting strong analyst attentionFree Stock Index Interpretation - Jammu Links News
What analysts say about Cingulate Inc. Equity Warrant stockInvest confidently with real-time market updates - Jammu Links News
What are the latest earnings results for Cingulate Inc. Equity WarrantBuild a diversified portfolio for steady profits - Jammu Links News
Is it the right time to buy Cingulate Inc. stockUnlock powerful market trend analysis - Jammu Links News
What institutional investors are buying Cingulate Inc. Equity Warrant stockFree Investment Timing Strategies - Jammu Links News
What is Cingulate Inc. Equity Warrant company’s growth strategyExplosive returns - Jammu Links News
What are the technical indicators suggesting about Cingulate Inc.Uncover the best stocks for explosive growth - Jammu Links News
What is the dividend policy of Cingulate Inc. stockBuild a strong portfolio for growth and safety - Jammu Links News
What makes Cingulate Inc. stock price move sharplyUnlock powerful insights from market experts - Jammu Links News
What catalysts could drive Cingulate Inc. Equity Warrant stock higher in 2025Phenomenal capital appreciation - Jammu Links News
What catalysts could drive Cingulate Inc. stock higher in 2025Double-digit growth - Jammu Links News
What are the technical indicators suggesting about Cingulate Inc. Equity WarrantExplosive wealth accumulation - Jammu Links News
Is Now a Good Time to Reenter Cingulate Inc.Low Risk Picks for Daily Trading Released - metal.it
What are analysts’ price targets for Cingulate Inc. in the next 12 monthsBreakout Stocks Tips That Work - Jammu Links News
What markets is VERB expanding into Is Cingulate Inc. stock a good long term investment optionStock Strategy Entry Points Backed By Experts - jammulinksnews.com
Cingulate gets $4.3M waiver, clearing way to submit for FDA approval - The Business Journals
Analysts Backtest Strategies on Cingulate Inc. Equity Warrant With Promising ResultsHigh Return Conservative Stocks - beatles.ru
How volatile is Cingulate Inc. stock compared to the marketFinancial News Tips To Watch Now - jammulinksnews.com
0.24%
3.39%
자본화:
|
볼륨(24시간):